High Frequency of B Cells Capable of Producing Anti-Thyrotropin Receptor Antibodies in Patients with Graves' Disease

Ji Lao Fan, Rajesh K. Desai, John S. Dallas, Neelam M. Wagle, Gattadahalli Seetharamaiah, Bellur S. Prabhakar

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Hyperthyroidism in Graves' disease (GD) is mediated by antibodies to the thyrotropin receptor (TSHr). Patients that go into remission show a decline in antibody titer. However, upon cessation of treatment with anti-thyroid drugs a significant proportion of patients relapse and TSHr antibodies (TSHrAb) are present in their circulation. This suggests that B cells capable of producing TSHrAb persist despite treatment. To determine the frequency of these cells, B cells from six patients with GD and four healthy controls were infected with Epstein-Barr virus and cultured in 96-well plates at varying cell concentrations. A higher frequency of B cells capable of producing TSHrAbs was detected in patients with GD, relative to normal controls. For example, at 2 × 105 cells per well, 100% of wells containing cells from either patients with GD or controls were positive for immunoglobulin (Ig) production. In contrast, 27% of the wells containing cells from Graves' patients, and only 3% from controls, were positive for TSHrAb. Higher titers of TSHrAbs were produced in cultures containing lymphocytes from patients with GD and were predominantly of IgG isotype. All patients with GD who had high thyrotropin binding inhibitory immunoglobulins also had higher frequencies of TSHr-specific B cells. These findings show that TSHrAb-producing B cells are present at a higher frequency in the peripheral circulation of patients with GD.

Original languageEnglish (US)
Pages (from-to)69-74
Number of pages6
JournalClinical Immunology and Immunopathology
Volume71
Issue number1
DOIs
StatePublished - Apr 1994
Externally publishedYes

Fingerprint

Thyrotropin Receptors
Graves Disease
B-Lymphocytes
Antibodies
Antibody-Producing Cells
Withholding Treatment
Hyperthyroidism
Human Herpesvirus 4
Immunoglobulins
Thyroid Gland
Immunoglobulin G
Lymphocytes
Recurrence

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Immunology and Allergy
  • Immunology

Cite this

High Frequency of B Cells Capable of Producing Anti-Thyrotropin Receptor Antibodies in Patients with Graves' Disease. / Fan, Ji Lao; Desai, Rajesh K.; Dallas, John S.; Wagle, Neelam M.; Seetharamaiah, Gattadahalli; Prabhakar, Bellur S.

In: Clinical Immunology and Immunopathology, Vol. 71, No. 1, 04.1994, p. 69-74.

Research output: Contribution to journalArticle

Fan, Ji Lao ; Desai, Rajesh K. ; Dallas, John S. ; Wagle, Neelam M. ; Seetharamaiah, Gattadahalli ; Prabhakar, Bellur S. / High Frequency of B Cells Capable of Producing Anti-Thyrotropin Receptor Antibodies in Patients with Graves' Disease. In: Clinical Immunology and Immunopathology. 1994 ; Vol. 71, No. 1. pp. 69-74.
@article{4bd167eebc304cd892e74943bba87630,
title = "High Frequency of B Cells Capable of Producing Anti-Thyrotropin Receptor Antibodies in Patients with Graves' Disease",
abstract = "Hyperthyroidism in Graves' disease (GD) is mediated by antibodies to the thyrotropin receptor (TSHr). Patients that go into remission show a decline in antibody titer. However, upon cessation of treatment with anti-thyroid drugs a significant proportion of patients relapse and TSHr antibodies (TSHrAb) are present in their circulation. This suggests that B cells capable of producing TSHrAb persist despite treatment. To determine the frequency of these cells, B cells from six patients with GD and four healthy controls were infected with Epstein-Barr virus and cultured in 96-well plates at varying cell concentrations. A higher frequency of B cells capable of producing TSHrAbs was detected in patients with GD, relative to normal controls. For example, at 2 × 105 cells per well, 100{\%} of wells containing cells from either patients with GD or controls were positive for immunoglobulin (Ig) production. In contrast, 27{\%} of the wells containing cells from Graves' patients, and only 3{\%} from controls, were positive for TSHrAb. Higher titers of TSHrAbs were produced in cultures containing lymphocytes from patients with GD and were predominantly of IgG isotype. All patients with GD who had high thyrotropin binding inhibitory immunoglobulins also had higher frequencies of TSHr-specific B cells. These findings show that TSHrAb-producing B cells are present at a higher frequency in the peripheral circulation of patients with GD.",
author = "Fan, {Ji Lao} and Desai, {Rajesh K.} and Dallas, {John S.} and Wagle, {Neelam M.} and Gattadahalli Seetharamaiah and Prabhakar, {Bellur S.}",
year = "1994",
month = "4",
doi = "10.1006/clin.1994.1053",
language = "English (US)",
volume = "71",
pages = "69--74",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - High Frequency of B Cells Capable of Producing Anti-Thyrotropin Receptor Antibodies in Patients with Graves' Disease

AU - Fan, Ji Lao

AU - Desai, Rajesh K.

AU - Dallas, John S.

AU - Wagle, Neelam M.

AU - Seetharamaiah, Gattadahalli

AU - Prabhakar, Bellur S.

PY - 1994/4

Y1 - 1994/4

N2 - Hyperthyroidism in Graves' disease (GD) is mediated by antibodies to the thyrotropin receptor (TSHr). Patients that go into remission show a decline in antibody titer. However, upon cessation of treatment with anti-thyroid drugs a significant proportion of patients relapse and TSHr antibodies (TSHrAb) are present in their circulation. This suggests that B cells capable of producing TSHrAb persist despite treatment. To determine the frequency of these cells, B cells from six patients with GD and four healthy controls were infected with Epstein-Barr virus and cultured in 96-well plates at varying cell concentrations. A higher frequency of B cells capable of producing TSHrAbs was detected in patients with GD, relative to normal controls. For example, at 2 × 105 cells per well, 100% of wells containing cells from either patients with GD or controls were positive for immunoglobulin (Ig) production. In contrast, 27% of the wells containing cells from Graves' patients, and only 3% from controls, were positive for TSHrAb. Higher titers of TSHrAbs were produced in cultures containing lymphocytes from patients with GD and were predominantly of IgG isotype. All patients with GD who had high thyrotropin binding inhibitory immunoglobulins also had higher frequencies of TSHr-specific B cells. These findings show that TSHrAb-producing B cells are present at a higher frequency in the peripheral circulation of patients with GD.

AB - Hyperthyroidism in Graves' disease (GD) is mediated by antibodies to the thyrotropin receptor (TSHr). Patients that go into remission show a decline in antibody titer. However, upon cessation of treatment with anti-thyroid drugs a significant proportion of patients relapse and TSHr antibodies (TSHrAb) are present in their circulation. This suggests that B cells capable of producing TSHrAb persist despite treatment. To determine the frequency of these cells, B cells from six patients with GD and four healthy controls were infected with Epstein-Barr virus and cultured in 96-well plates at varying cell concentrations. A higher frequency of B cells capable of producing TSHrAbs was detected in patients with GD, relative to normal controls. For example, at 2 × 105 cells per well, 100% of wells containing cells from either patients with GD or controls were positive for immunoglobulin (Ig) production. In contrast, 27% of the wells containing cells from Graves' patients, and only 3% from controls, were positive for TSHrAb. Higher titers of TSHrAbs were produced in cultures containing lymphocytes from patients with GD and were predominantly of IgG isotype. All patients with GD who had high thyrotropin binding inhibitory immunoglobulins also had higher frequencies of TSHr-specific B cells. These findings show that TSHrAb-producing B cells are present at a higher frequency in the peripheral circulation of patients with GD.

UR - http://www.scopus.com/inward/record.url?scp=0028351237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028351237&partnerID=8YFLogxK

U2 - 10.1006/clin.1994.1053

DO - 10.1006/clin.1994.1053

M3 - Article

C2 - 8137560

AN - SCOPUS:0028351237

VL - 71

SP - 69

EP - 74

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -